Moderna RSV Vaccine Demonstrates High Efficacy Against Severe Hospitalizations in Older Adults
A recent study published in JAMA Network Open reveals that Moderna's mResvia RSV vaccine offers robust protection against severe respiratory syncytial virus outcomes among older U.S. veterans.
🧠AI AnalysisPhoto: Medical Xpress
Key points
- Moderna's mResvia vaccine showed 81.8% effectiveness against RSV hospitalizations.
- The study analyzed 74,926 vaccinated veterans matched against 286,425 controls.
- Protection against documented infections varied by age, dropping in adults 80 and older.
A single dose of Moderna's mResvia respiratory syncytial virus vaccine delivered notable protection against severe illness, urgent care visits, and hospitalizations among older U.S. veterans, according to a study recently published in JAMA Network Open. Authored by David P. Bui and colleagues, the investigation utilized a target trial framework to examine veterans aged 50 and older receiving care within the Veterans Health Administration between October 1, 2025, and January 31, 2026.
The findings indicate that the vaccine achieved 81.8% effectiveness against RSV-associated hospitalizations. Additionally, the single dose provided 60.3% protection against documented RSV infections and 60.2% protection against urgent care or emergency department encounters. Researchers successfully matched 74,926 vaccinated individuals with 286,425 unique unvaccinated controls across four sequential monthly trials, tracking participants for a period of 24 weeks.
While the vaccine demonstrated positive outcomes across various demographics, effectiveness against documented infections varied by age, declining from 82.9% in the 50-to-59 age bracket down to 28.6% among adults aged 80 and older. The authors noted that the mRNA-1345 vaccine showed effectiveness comparable to protein-based RSV vaccines evaluated in prior seasons, though they emphasized that extended monitoring is necessary to evaluate protection durability across multiple years.
What to know: The U.S. Food and Drug Administration originally approved the vaccine in May 2024 for adults aged 60 and older, later expanding that indication in June 2025 to include individuals aged 18 to 59 at increased risk for lower respiratory tract disease caused by RSV. Patients should consult a healthcare provider to discuss personal vaccination choices and individual risk factors.
Source Medical Xpress — medicalxpress.com/news/2026-11-moderna-rsv-vaccine-shown-strong.html ↗
Read next
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…
🏥Public HealthRecall Issued for Generic Propranolol Over Potential Metal Contamination
Breckenridge Pharmaceutical has initiated a voluntary recall of one lot of generic propranolol capsules due to the potential presence of metal fragments.